

Resource Summary Report

Generated by [dkNET](#) on Aug 22, 2026

InVivoMAb polyclonal Armenian hamster IgG

RRID:AB_1107773

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0091, RRID:AB_1107773)

Antibody Information

URL: http://antibodyregistry.org/AB_1107773

Proper Citation: (Bio X Cell Cat# BE0091, RRID:AB_1107773)

Host Organism: armenian hamster

Clonality: polyclonal

Antibody Name: InVivoMAb polyclonal Armenian hamster IgG

Description: This polyclonal targets

Antibody ID: AB_1107773

Vendor: Bio X Cell

Catalog Number: BE0091

Alternative Catalog Numbers: BE0091-50MG, BE0091-1MG, BE0091-100MG, BE0091-5MG, BE0091-25MG

Record Creation Time: 20260114T193114+0000

Record Last Update: 20260225T232014+0000

Ratings and Alerts

No rating or validation information has been found for InVivoMAb polyclonal Armenian hamster IgG.

No alerts have been found for InVivoMAb polyclonal Armenian hamster IgG.

Data and Source Information

Usage and Citation Metrics

We found 85 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang Y, et al. (2026) Preoperative exercise induces anti-tumor Kupffer cells to prevent surgical stress-promoted colorectal cancer liver metastasis. *Cell reports. Medicine*, 7(2), 102589.

Hernández-Verdin I, et al. (2026) GABA promotes resistance to immunotherapy in patients with TLS-positive tumors. *Cancer cell*.

Yang L, et al. (2026) IL-1R1-positive dorsal raphe neurons drive self-imposed social withdrawal in sickness. *Cell*, 189(1), 272.

Qiao S, et al. (2026) Microbiota utilization of intestinal amino acids modulates cancer progression and anticancer immunity. *Cell host & microbe*, 34(1), 18.

Crotts SB, et al. (2026) ST8Sia6-dependent glycosylation restrains gut inflammation and pathogenic Th1 and Th17 programs. *Cell reports*, 45(5), 117347.

Lu T, et al. (2026) Dysplastic epithelial repair promotes the tissue residence of lymphocytes to inhibit alveolar regeneration post viral infection. *Cell stem cell*, 33(1), 108.

Scharping NE, et al. (2026) Proteostasis sustains T cell differentiation potential and tumor-infiltrating lymphocyte function. *Cell*, 189(10), 2857.

Pandya T, et al. (2026) Plasma signals of lung tumor promotion for molecular cancer prevention. *Cell*, 189(13), 3903.

Boutet M, et al. (2025) Mutations in MLL3 promote breast cancer progression via HIF1 α -dependent intratumoral recruitment and differentiation of regulatory T cells. *Immunity*, 58(8), 2035.

Kim SH, et al. (2025) IL-10 sensing by lung interstitial macrophages prevents bacterial dysbiosis-driven pulmonary inflammation and maintains immune homeostasis. *Immunity*, 58(5), 1306.

Dhenni R, et al. (2025) Macrophages direct location-dependent recall of B cell memory to vaccination. *Cell*, 188(13), 3477.

Weber-Delacroix E, et al. (2025) Regulatory T Cells Poise the Myeloid Landscape after Chemotherapy in Lung Tumors. *Cancer immunology research*, 13(10), 1561.

Oswald BM, et al. (2025) Dietary restriction reprograms CD8 $^{+}$ T cell fate to enhance anti-tumour immunity and immunotherapy responses. *Nature metabolism*, 7(12), 2489.

Goepp M, et al. (2025) Age-related impairment of intestinal inflammation resolution through an eicosanoid-immune-microbiota axis. *Cell host & microbe*, 33(5), 671.

Garner H, et al. (2025) Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread. *Cancer cell*, 43(7), 1279.

Ciecko AE, et al. (2025) An interleukin-27-centered cytokine circuit regulates macrophage and T cell interactions in autoimmune diabetes. *iScience*, 28(10), 113537.

Hou Y, et al. (2025) Optimizing stem cell infusion timing in the prevention of acute graft-versus-host disease. *Cell*, 188(11), 3030.

Jin S, et al. (2025) V-domain immunoglobulin suppressor of T-cell activation and programmed death receptor 1 dual checkpoint blockade enhances antitumour immunity and survival in glioblastoma. *British journal of pharmacology*, 182(6), 1306.

Mujal AM, et al. (2025) Splenic TNF- α signaling potentiates the innate-to-adaptive transition of antiviral NK cells. *Immunity*, 58(3), 585.

Yamane K, et al. (2025) ULBP2 Promotes Tumor Progression by Suppressing NKG2D-Mediated Anti-Tumor Immunity. *International journal of molecular sciences*, 26(7).